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SLEEP INTERVENTIONS FOR OSTEOARTHRITIS AND SPINAL PAIN: A
SYSTEMATIC REVIEW OF RANDOMIZED CONTROL TRIALS
P.H. Ferreira y, K.K. Ho y, M.B. Pinheiro y, D. Aquino Silva z, C. Miller x,
R. Grunstein x, M. Simic y. yUniv. of Sydney, Sydney, Australia; zUniv.e
Federal de Minas Gerais, Belo Horizonte, Brazil; xCIRUS, Sydney, Australia
Purpose: To determine if sleep interventions improve pain and sleep in
people with osteoarthritis and/or spinal pain.
Methods: An electronic database search was conducted in Medline,
Embase, AMED, PsycINFO, CENTRAL, CINAHL and PEDro from their
inception date to April 2016. Keywords relating to “sleep”, “osteo-
arthritis”, “spinal pain”, and “randomized control trial” were com-
bined. Eligible studies were randomized control trials (RCT) from
peer reviewed journals which investigated the use of sleep inter-
ventions for people with osteoarthritis and/or spinal pain. Sleep
interventions were defined as interventions which aim to directly
improve sleep related outcomes, including both non-pharmacological
and pharmacological methods. Two investigators independently
screened the literature search (title and abstract, followed by full
text), extracted data and assessed methodological quality of included
studies. Meta-analyses were performed to pool effect sizes for pain
and sleep quality. Sensitivity analyses were performed with the fol-
lowing criteria: osteoarthritis or spinal pain, any sleep intervention,
compared to a control/placebo group, 10 participants per group and
PEDro Score6/10. The review protocol was registered with the
International Prospective Register of Systematic Reviews
(CRD42016036315).
Results: Of 1199 unique records, 97 underwent full text screening and
22 studies were included. 14 studies examined spinal pain, six for
osteoarthritis, and two were mixed. Sleep interventions were cognitive
behavioural therapy (CBT) (n ¼ 8), pillows (n ¼ 4), sleep medication
(n ¼ 3), exercise (n ¼ 2), massage (n ¼ 2), music (n ¼ 1), acupuncture
(n¼ 1), andmattresses (n¼ 1). Intervention periods ranged from four to
ten weeks. Seven studies combined sleep and pain interventions,
however none combined CBT for sleep with exercise or physiotherapy.
Overall pooled post-treatment results (mean age ¼ 33-73 years,
n ¼ 1339) had high heterogeneity scores ranging from 62-95%. Random
effects estimates showed that sleep interventions led to significant
improvements in pain (standardized mean difference 4.94, 95% con-
fidence interval [1.47-8.42], P ¼ 0.005) and sleep quality (9.13, [4.36-
13.90], P<0.001). After sensitivity analyses, 7 RCTs were incorporated
into the meta-analysis (mean age ¼ 42 to 72 years, n ¼ 354), with
heterogeneity scores ranging from 10-45%. The pooled fixed effect
estimates showed significant improvements in pain (10.78, [6.84-
14.72]; P<0.001) and sleep quality (8.21, [4.83-11.58]; P<0.001).
Conclusions: Sleep interventions alone are likely to improve pain and
sleep quality for people with osteoarthritis and/or spinal pain. Although
the magnitude of change may not be clinically significant, further high-
quality studies using CBT for sleep in conjunction with other inter-
ventions for people with osteoarthritis and/or spinal pain should be
conducted.
463
TPX-100 LEADS TO MARKED, SUSTAINED IMPROVEMENTS IN
SUBJECTS WITH KNEE OSTEOARTHRITIS: PRE-CLINICAL RATIONALE
AND RESULTS OF A CONTROLLED CLINICAL TRIAL
D. McGuire y, N. Lane z, N. Segal x, S. Metyas k, H. Barthel ¶, M. Miller y,
D. Rosen y, Y. Kumagai y. yOrthoTrophix, Oakland, CA, USA; zUniv. of
California, Davis, Sacramento, CA, USA; xKansas Univ. Clinical Res. Ctr.,
Kansas City, KS, USA; kCovina Arthritis Ctr., Covina, CA, USA; ¶Barthel
Clinic, Santa Barbara, CA, USA
Purpose: TPX-100 is a 23-amino acid peptide derived from Matrix
Extracellular Phosphoglycoprotein (MEPE), a Small Integrin-Binding
Ligand, N-linked Glycoprotein (SIBLING) family protein. TPX-100 has
been shown to induce articular cartilage proliferation in goats (N ¼ 8/
dose group) after a standardized full-thickness chondral defect and
treatment with 4 weekly intra-articular (IA) injections of TPX-100 vs.
vehicle (25, 125 or 250 mg/injection). After 6 months, histopathological
staining in TPX-100-treated joints indicated robust articular (hyaline)
cartilage formation. Additionally, IA TPX-100 reduced joint damage and
improved osteoarthritis scores vs. vehicle in rats after standardized ACL
transection and partial medial meniscectomy. This Phase 2 study eval-
uated safety, tolerability and preliminary efficacy of TPX-100 by IAadministration in subjects with bilateral patellofemoral osteoarthritis
(PFOA). Each subject served as his/her own control, intended to mini-
mize effects of age, sex, genetic factors, and activity levels on outcome
measures.
Methods: Subjects with ICRS grade 2-3 PFOA, confirmed by centrally-
read screening MRI, were enrolled at 15 sites. One knee was randomly
assigned to receive 4 weekly injections of TPX-100, while the con-
tralateral knee received placebo injections. Investigator, subject, site
and sponsor were blinded to treatment assignment. In Part A of the
study, 4 dose cohorts (n ¼ 6e9 subjects/cohort) received 20, 50, 100 or
200 mg/injection. Safety/tolerability of each cohort was evaluated by a
Safety Review Committee (SRC). In Part B, all subjects received 200 mg/
injection. Quantitative MRIs, obtained at baseline, 6 and 12 months,
were read centrally. Validated patient-reported outcomes (PROs)
included the Knee Osteoarthritis Outcome Score (KOOS), appropriate
for younger, more athletic subjects, and the Western Ontario McMaster
Universities Osteoarthritis Index (WOMAC).
Results: All subjects who received 4 weekly 200 mg injections, with at
least one follow-up MRI, were analyzed (n ¼ 93 subjects, 186 knees).
The study population was typical of the knee OA population in the U.S.
(median age, 58.4 years; BMI 30.3), and 68 of 93 subjects (73%) also had
ICRS grade 2 e 4 mild to severe bilateral tibio-femoral osteoarthritis
(TFOA). Safety: There were no drug-related SAEs and no dose-limiting
toxicities across doses. Common adverse events such as knee pain had
virtually identical incidences in control and TPX-100-treated knees.
Efficacy: Only 14% of knees changed in cartilage thickness/volume over
the 12 months of the study. Quantitative MRI revealed no measurable
between-knee structural differences in this small sample. However,
statistically significant (P<0.05) and clinically meaningful differences in
KOOS and WOMAC scores were demonstrated compared with placebo-
exposed knees at 6 or 12 months or both, including activities of daily
living, sports activities, and knee-related quality of life. Comparing TPX-
100 treated knees vs. control knees, at 12 months; there was a sig-
nificant difference in pain ascending and descending stairs, a chief
complaint in PFOA. Overall, use of analgesics, including non-steroidal
anti-inflammatory medications, declined markedly (62.5%) during the
study.
Conclusions: TPX-100, administered in 4 weekly intra-articular injec-
tions (200 mg/injection), is safe, well tolerated, and associated with
statistically significant and clinically meaningful functional benefits
sustained to at least 12 months. Improvement in knee functional status
with reduction in disease burden represents a key therapeutic goal in
OA therapeutic development. The small sample size of knees with MRI
changes in cartilage thickness/volume limited the power of this study to
detect differences between knees in these measures. However, pre-
clinical large and small animal data indicate the structure-modifying
potential of TPX-100, which may be demonstrated with a longer study
involving a larger sample size.
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SELF-REPORTED HOME EXERCISE ADHERENCE e FACT OR FICTION?
A VALIDITY AND RELIABILITY STUDY USING CONCEALED
ACCELEROMETRY AMONG PEOPLE WITH KNEE OSTEOARTHRITIS
P.J. Nicolson y, R.S. Hinman y, T.V. Wrigley y, P.W. Stratford z,
K.L. Bennell y. yUniv. of Melbourne, Melbourne, Australia; zMcMaster
Univ., Hamilton, ON, Canada
Purpose: The benefits of exercise for older adults with knee osteo-
arthritis (OA) are undisputed. Given the chronic nature of OA, home
exercise programs provide an economic and sustainable intervention
option. However, for these programs to be beneficial, patient adherence
is crucial. Self-reported adherence measures such as exercise diaries
and simple self-rated scales are commonly used both clinically and in
research, yet it has been acknowledged that these measures are vul-
nerable to reporting bias, particular over increasing periods of recall,
and little evidence exists demonstrating their validity or reliability. The
objectives of this study were threefold: (i) to examine concurrent val-
idity of adherence over 12 weeks measured via an exercise diary
compared to adherence simultaneously measured using a concealed
accelerometer in a cuff weight, among a cohort of older adults with
chronic knee pain undertaking a home strengthening program; (ii) to
examine the validity of a self-rated adherence scale with increasing
duration of recall from 2-12 weeks compared to accelerometer meas-
ured adherence; and (iii) to evaluate test-retest reliability of the self-
rated adherence scale.
